E

Euroapi SAS
PAR:EAPI

Watchlist Manager
Euroapi SAS
PAR:EAPI
Watchlist
Price: 3.17 EUR 0.32% Market Closed
Market Cap: 303m EUR
Have any thoughts about
Euroapi SAS?
Write Note
Section:
 

Relative Value

The Relative Value of one EAPI stock under the Base Case scenario is 7.74 EUR. Compared to the current market price of 3.17 EUR, Euroapi SAS is Undervalued by 59%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

EAPI Relative Value
Base Case
7.74 EUR
Undervaluation 59%
Relative Value
Price
E
Worst Case
Base Case
Best Case

Valuation Multiples

0.3
P/S
P/S
Price to Sales
0.3
vs History
50
vs Industry
88
Median 3Y
0.4
Median 5Y
0.4
Industry
2.5
Forward
0.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
37
Median 3Y
-1.9
Median 5Y
-1.9
Industry
21.4
Forward
-7.6
More Details
2.6
P/OCF
P/OCF
Price to OCF
2.6
vs History
62
vs Industry
7
Median 3Y
21.5
Median 5Y
21.5
Industry
16
More Details
1.3
P/FCFE
P/FCFE
Price to FCFE
1.3
vs History
25
vs Industry
25
Median 3Y
-10.4
Median 5Y
-10.4
Industry
23.3
More Details
0.3
P/B
P/B
Price to Book Value
0.3
vs History
65
vs Industry
78
Median 3Y
0.6
Median 5Y
0.6
Industry
2.1
More Details
0.5
EV/S
EV/S
Enterprise Value to Sales
0.5
vs History
50
vs Industry
85
Median 3Y
0.6
Median 5Y
0.6
Industry
2.6
Forward
0.5
More Details
2.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.9
vs History
53
vs Industry
62
Median 3Y
3.4
Median 5Y
3.4
Industry
5.1
More Details
1.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
1.6
vs History
53
vs Industry
49
Median 3Y
1.8
Median 5Y
1.8
Industry
13.7
Forward
8.1
More Details
113.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
113.1
vs History
12
vs Industry
3
Median 3Y
74.1
Median 5Y
74.1
Industry
16.7
Forward
-13.4
More Details
4.2
EV/OCF
EV/OCF
Enterprise Value to OCF
4.2
vs History
62
vs Industry
4
Median 3Y
22.5
Median 5Y
22.5
Industry
15.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-12.1
Median 5Y
-12.1
Industry
18.9
More Details
0.4
EV/IC
EV/IC
Enterprise Value to IC
0.4
vs History
62
vs Industry
80
Median 3Y
0.5
Median 5Y
0.5
Industry
1.9
More Details

Multiples Across Competitors

EAPI Competitors Multiples
Euroapi SAS Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Euroapi SAS
PAR:EAPI
302m EUR 0.3 -1.1 1.6 113.1
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
747.7B USD 18.3 89.3 48 53.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.8T DKK 10.3 29.4 20.4 23.3
US
Johnson & Johnson
NYSE:JNJ
342.5B USD 3.9 23.3 11.3 14.7
US
Merck & Co Inc
NYSE:MRK
252.8B USD 4 20.8 10.5 12.6
CH
Roche Holding AG
SIX:ROG
216.7B CHF 3.7 18.8 10.6 12.5
UK
AstraZeneca PLC
LSE:AZN
170.2B GBP 4.3 32.5 169.2 253.5
CH
Novartis AG
SIX:NOVN
179.3B CHF 3.9 11.2 9.7 13.5
US
Pfizer Inc
NYSE:PFE
152.2B USD 2.5 35.8 10.6 16
P/S Multiple
Revenue Growth P/S to Growth
FR
E
Euroapi SAS
PAR:EAPI
Average P/S: 382 942
0.3
-2%
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
7%
601 676.1
US
Eli Lilly and Co
NYSE:LLY
18.3
28%
0.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
9%
64.3
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
21%
0.5
US
Johnson & Johnson
NYSE:JNJ
3.9
4%
1
US
Merck & Co Inc
NYSE:MRK
4
6%
0.7
CH
Roche Holding AG
SIX:ROG
3.7
5%
0.7
UK
AstraZeneca PLC
LSE:AZN
4.3
10%
0.4
CH
Novartis AG
SIX:NOVN
3.9
6%
0.7
US
Pfizer Inc
NYSE:PFE
2.5
3%
0.8
P/E Multiple
Earnings Growth PEG
FR
E
Euroapi SAS
PAR:EAPI
Average P/E: 32.6
Negative Multiple: -1.1 		N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
89.3
76%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29.4
23%
1.3
US
Johnson & Johnson
NYSE:JNJ
23.3
-8%
N/A
US
Merck & Co Inc
NYSE:MRK
20.8
320%
0.1
CH
Roche Holding AG
SIX:ROG
18.8
16%
1.2
UK
AstraZeneca PLC
LSE:AZN
32.5
40%
0.8
CH
Novartis AG
SIX:NOVN
11.2
9%
1.2
US
Pfizer Inc
NYSE:PFE
35.8
102%
0.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
E
Euroapi SAS
PAR:EAPI
Average EV/EBITDA: 413.8
1.6
-30%
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48
42%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
DK
Novo Nordisk A/S
CSE:NOVO B
20.4
22%
0.9
US
Johnson & Johnson
NYSE:JNJ
11.3
4%
2.8
US
Merck & Co Inc
NYSE:MRK
10.5
63%
0.2
CH
Roche Holding AG
SIX:ROG
10.6
7%
1.5
UK
AstraZeneca PLC
LSE:AZN
169.2
18%
9.4
CH
Novartis AG
SIX:NOVN
9.7
3%
3.2
US
Pfizer Inc
NYSE:PFE
10.6
9%
1.2
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
E
Euroapi SAS
PAR:EAPI
Average EV/EBIT: 1 821.5
113.1
115%
1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.6
45%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
DK
Novo Nordisk A/S
CSE:NOVO B
23.3
22%
1.1
US
Johnson & Johnson
NYSE:JNJ
14.7
9%
1.6
US
Merck & Co Inc
NYSE:MRK
12.6
98%
0.1
CH
Roche Holding AG
SIX:ROG
12.5
9%
1.4
UK
AstraZeneca PLC
LSE:AZN
253.5
32%
7.9
CH
Novartis AG
SIX:NOVN
13.5
17%
0.8
US
Pfizer Inc
NYSE:PFE
16
19%
0.8

See Also

Summary
EAPI intrinsic value, competitors valuation, and company profile.
DCF Valuation
EAPI stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EAPI stock valuation using valuation multiples.
Wall Street Estimates
EAPI price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EAPI stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 215,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.